Valencia Town Center Pharmacy
Community pharmacy in Valencia, California

Dapoxetine (Priligy): U.S. Regulatory and Product Guide

Dapoxetine is an active ingredient marketed under the brand name Priligy in a number of non-U.S. countries for premature ejaculation. It is not an FDA-approved prescription drug product in the United States. A foreign-authorized Priligy product should not be presented as though it were an FDA-approved U.S. product.

Priligy is a foreign-market product, not a U.S. OTC product

The European Medicines Agency has published regulatory material for Priligy describing dapoxetine as the active substance and Priligy as a prescription medicine used for premature ejaculation in men 18 to 64 years old. The EMA referral specifically addressed 30 mg and 60 mg tablets and concluded that the 60 mg strength’s benefits outweighed its risks in the European authorization context under review.

That European regulatory history does not create FDA approval in the United States. An Australian public assessment report also documents that a U.S. New Drug Application for dapoxetine received a “not-approvable” action in 2005. Current U.S. product research does not identify an FDA-approved Priligy/dapoxetine label comparable with the current DailyMed labels available for approved U.S. prescription drugs.

Priligy is a prescription medicine in the foreign markets represented by the regulator sources, and dapoxetine is not an FDA-approved U.S. OTC product.

30 mg and 60 mg do not prove U.S. approval

Foreign Priligy product information commonly distinguishes 30 mg and 60 mg film-coated tablets. Those strengths are useful for identifying the foreign product being discussed, but they are not evidence that a seller’s dapoxetine tablets are authorized for U.S. distribution.

When evaluating a product listing, a U.S. consumer should ask which country authorized the product, which company is responsible for the label, whether the package corresponds to that country’s official product information, and whether the product is being represented accurately in the United States. A statement such as “same ingredient” is not equivalent to FDA approval.

Avoiding false equivalence with other SSRIs

Dapoxetine is an SSRI, but it should not be presented as interchangeable with FDA-approved U.S. antidepressants. The EMA describes its specific foreign-market use for premature ejaculation. Different active ingredients have different pharmacokinetics, indications, labeling and safety restrictions.

Using another SSRI off-label as a substitute or combining dapoxetine with other serotonergic medicines are clinical decisions, not product-shopping comparisons.

What a U.S. patient should verify

For a medication that lacks an FDA-approved U.S. product, the key question is regulatory identity before price. A consumer should be cautious with websites that use U.S.-style pharmacy language while selling a foreign package without clearly identifying the country of authorization, manufacturer, prescription requirements and legal distribution channel.

Patients seeking treatment for premature ejaculation in the United States should discuss FDA-approved or otherwise clinically appropriate options with a licensed prescriber. A pharmacist can also help distinguish an FDA-approved U.S. product from a foreign-market medicine or an unverified online listing.

Valencia Town Center Pharmacy

Contact the pharmacy to confirm current availability, product identity and coverage for a specific prescription.

Foreign authorization should be identified by market

Priligy illustrates a common problem in medication research: a real regulated medicine can be authorized in one market and unapproved in another. The EMA material establishes a European regulatory history for Priligy, while the Australian TGA assessment provides another national-regulator record. Neither source should be converted into a statement that FDA approved Priligy.

For a U.S. reader, a seller should be able to identify the country for which the package was authorized. A package leafleted for a European or other foreign market may be genuine for that market but still not be an FDA-approved U.S. drug product. “Foreign authorized,” “FDA approved,” and “available in the United States” are separate questions.

Price is secondary to regulatory identity

A low online price for dapoxetine does not answer the most important product question. Before comparing cost, a consumer would need to know what product is being offered, which regulator authorized it, who manufactured it and through what legal channel it is being supplied. Without that information, a numerical price comparison can create false confidence.

For broader patient-facing information, see Medication & Pharmacy Resources.